Protocol design can have a significant impact on patient engagement and clinical trial performance. In this live webinar, explore the findings of a recent scholarly study conducted by the Center for the Study of Drug Development (CSDD) at Tufts University School of Medicine which characterize current protocol design practices and their effects on study volunteer experience and clinical trial performance.

Some of the topics that will be covered by our featured speaker include:

Benchmarks on industry-funded clinical trial protocol scope and structure
Overall and study-specific study timelines
Patient recruitment and retention rates
Study volunteer participation experience
New practices in protocol design

Finally, the speaker will provide insights on how small, medium and large sponsors can implement these new practices to optimize patient engagement, lower clinical cost and accelerate clinical trial speed.

Keywords:

Speaker

Ken Getz, Director of Sponsored Research Programs & Associate Professor, Tufts CSDD

Kenneth A. Getz is the director of Sponsored Research and an associate professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine. His research focuses on drug development management strategies and tactics; protocol design practices; and global outsourcing, investigative site and patient recruitment practices and policies. He is also the chairman and founder of The Center for Information and Study on Clinical Research Participation (CISCRP) – a nonprofit organization dedicated to educating and raising public and patient awareness of the clinical research enterprise.

A well-known speaker at conferences, symposia, universities, investor meetings and corporations, Ken has published extensively in peer-review journals, books and in the trade press and writes a bi-monthly column nominated for a Neal Award in Applied Clinical Trials. He holds a number of board appointments in the private and public sectors including WCG and ORA and serves on the editorial boards of Pharmaceutical Medicine and Therapeutic Innovation and Regulatory Science. Ken received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a Bachelor’s Degree from Brandeis University. Ken is the founder of CenterWatch, a leading publisher in the clinical trials industry.

Message Presenter

Who Should Attend?

Organization types:

CROs
Early-phase pharma
Medical device
Diagnostics

Roles:

Data managers
Clinical trial site managers
ClinOps professionals

What You Will Learn

In this webinar, participants will learn about:

Benchmarks on industry-funded clinical trial protocol scope and structure
Overall and study-specific study timelines
Patient recruitment and retention rates
Study volunteer participation experience
Implementing new practices in protocol design

Xtalks Partners

Medrio

Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company’s cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient-reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit www.medrio.com.

Tufts

The Center for the Study of Drug Development (CSDD) at Tufts University School of Medicine is an internationally recognized nonprofit academic research center. Its mission is to provide strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical innovation. For nearly 40 years, CSDD has conducted scholarly analyses that address the economic, scientific, legal, political and management issues that affect the development and regulation of human therapeutics. CSDD’s multidisciplinary faculty has diverse backgrounds in economics, law, business, basic and clinical pharmacology, product development, medicine, and public health. To achieve its mission, CSDD interacts regularly with research-based life sciences companies, FDA and other regulatory agencies, policy-makers, contract research organizations, investors, consultancies, and academic institutions worldwide.